|
Study group
|
No.
|
Age (yr)
|
Gender (M/F)
|
Glucosepane (nM)
|
|---|
|
Control
|
29
|
34.4 ± 8.2
|
14/15
|
13.6 (10.1–18.1)
|
|
eOA
|
28
|
43.3 ± 13.3*
|
12/16
|
18.7 (13.3–35.5)*,OOO
|
|
aOA, pre-TKR
|
38
|
70.7 ± 8.9***
|
15/23
|
76.3 (61.2–97.5)***
|
|
Non-RA
|
32
|
51.7 ± 18.1**
|
14/16
|
31.2 (20.3–45.2)**,OOO
|
|
eRA
|
35
|
60.4 ± 15.7***
|
13/22
|
46.1 (31.1–77.8)***,OOO
|
- Abbreviations: eOA Early-stage osteoarthritis, aOA Advanced osteoarthritis, TKR Total knee replacement, RA Rheumatoid arthritis, eRA Early-stage rheumatoid arthritis
- Data are median (lower – upper quartile). Significance: 5-group comparison – p < 0.001 (Kruskal-Wallis). For binary comparisons: *, ** and ***, p < 0.05, p < 0.01 and p < 0.001 with respect to plasma levels of healthy controls; ooo, p < 0.001 with respect to plasma levels of aOA, pre-TKR (Mann-Whitney U)
